Background Early antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19)
but currently available agents are expensive. Favipiravir is routinely used in many countries …

Objectives The objective of this trial is to assess whether early antiviral therapy in outpatients
with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or …

Background Despite vaccination, many remain vulnerable to coronavirus disease 2019
(COVID-19) and its complications. Oral antivirals to prevent COVID-19 progression are vital …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-
CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …

Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …

Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not
accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro …

Aim of the study-to assess the efficacy and safety of favipiravir for treatment of mild to
moderate coronavirus disease (COVID-19). Material and methods. An open-labeled …

The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality
among infected individuals across the world. High transmissibility rate of the causative virus …